Robust Call Option Activity Highlights Investor Optimism
The call options for Sun Pharmaceutical Industries Ltd with a strike price of ₹1800 and expiry on 30 March 2026 have witnessed an impressive 10,400 contracts traded, generating a turnover of ₹1158.612 lakhs. Open interest stands at 6,494 contracts, reflecting sustained investor engagement and confidence in the stock's upward trajectory. The underlying stock price currently trades at ₹1806.5, just marginally above the strike price, indicating that market participants are positioning for further gains in the near term.
Price Performance and Technical Strength
Sun Pharma is trading close to its 52-week high, just 2.19% shy of the peak price of ₹1851.2. The stock has outperformed its Pharmaceuticals & Biotechnology sector by 1.21% today and has recorded a consecutive three-day gain, delivering a cumulative return of 3.48% over this period. This positive momentum is further supported by the stock trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a strong technical uptrend.
Investor participation has also been on the rise, with delivery volumes reaching 29.62 lakh shares on 6 March, marking a 22.05% increase compared to the five-day average delivery volume. This heightened liquidity, combined with a 2% threshold of the five-day average traded value, suggests that the stock can comfortably absorb sizeable trades, with a trade size capacity of approximately ₹13.93 crore.
Market Capitalisation and Fundamental Upgrades
Sun Pharmaceutical Industries Ltd is a large-cap stock with a market capitalisation of ₹4,27,502 crore, underscoring its dominant position in the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score has recently improved to 72.0, earning it a Buy grade as of 23 February 2026, an upgrade from its previous Hold rating. This upgrade reflects enhanced confidence in the company’s fundamentals, growth prospects, and valuation metrics.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Expiry Patterns and Strike Price Concentration
The concentration of call option activity at the ₹1800 strike price with expiry on 30 March 2026 is particularly noteworthy. This strike price is closely aligned with the current market price, suggesting that traders are betting on the stock maintaining or surpassing this level within the next three weeks. The sizeable open interest at this strike indicates that many investors are either initiating bullish positions or rolling over existing ones, anticipating continued upward momentum.
Comparative Sector and Market Context
While Sun Pharma has gained 0.59% in the last trading session, the Pharmaceuticals & Biotechnology sector has declined by 0.52%, and the broader Sensex index has fallen by 2.23%. This relative outperformance highlights the stock’s resilience amid broader market weakness and sectoral pressures. Investors appear to be favouring Sun Pharma as a defensive yet growth-oriented play within the healthcare space.
Liquidity and Trading Viability
The stock’s liquidity profile supports active trading strategies, with delivery volumes and traded value comfortably accommodating large trades. This liquidity is crucial for options traders who require efficient entry and exit points without significant price impact. The combination of strong fundamentals, technical momentum, and liquid trading conditions makes Sun Pharma an attractive candidate for both institutional and retail investors seeking exposure to the pharmaceutical sector.
Want to dive deeper on Sun Pharmaceutical Industries Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Outlook and Investor Takeaways
Given the current market dynamics, Sun Pharmaceutical Industries Ltd is positioned favourably for further gains. The strong call option activity at near-the-money strike prices, combined with the recent upgrade to a Buy rating and a robust Mojo Score of 72.0, indicates growing investor conviction. The stock’s proximity to its 52-week high and consistent outperformance relative to its sector and the broader market further reinforce this positive outlook.
Investors should monitor the expiry on 30 March 2026 closely, as the resolution of these call options will provide clearer signals on market expectations. Additionally, the company’s large market capitalisation and liquidity profile make it a viable option for both long-term investors and short-term traders seeking exposure to the pharmaceutical sector’s growth potential.
Risks and Considerations
While the bullish positioning is evident, investors should remain cautious of potential volatility around the expiry date and broader market fluctuations. Regulatory developments, global pharmaceutical trends, and sector-specific challenges could impact the stock’s trajectory. It is prudent to balance the optimistic technical signals with fundamental vigilance and risk management strategies.
Summary
Sun Pharmaceutical Industries Ltd’s recent surge in call option trading activity underscores a strong bullish sentiment supported by solid fundamentals, technical strength, and favourable market positioning. The stock’s upgrade to a Buy rating, coupled with its large-cap status and liquidity, makes it a compelling candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector. As expiry approaches, market participants will be watching closely to gauge the sustainability of this momentum.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
